The sulfonylurea glyburide induces impairment of glucagon and growth hormone responses during mild insulin-induced hypoglycemia

What Was Tested

Researchers studied Glucagon in this randomized controlled trial publication.

The sulfonylurea (SU) glyburide may cause severe and prolonged episodes of hypoglycemia.

The researchers aimed at investigating the impact of glyburide on glucose counterregulatory hormones during stepwise hypoglycemic clamp studies.

Who Took Part

The study group was 16 volunteers.

PubMed indexes the participants as adults, both men and women.

The researchers performed stepwise hypoglycemic clamp studies in 16 healthy volunteers (7 women and 9 men aged 44 +/- 10 years).

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.

Because people in this Glucagon study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Glucagon study, the assignments were hidden from both participants and investigators until the end.

Some volunteers received a placebo instead of Glucagon, giving a reference point.

Each person switched between Glucagon and the comparison at some point, usually with a gap in between.

What Was Measured

PubMed files the paper under topics including Blood Glucose, Body Mass Index, Glucagon, Glucose Clamp Technique, Glyburide, Human Growth Hormone and Hypoglycemia.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Glucagon in 16 volunteers.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2002 (Diabetes care), a journal based in United States.

More context: the Glucagon compound page, all human trials.